Company intelligence / Profile preview

Predictive Health Diagnostics Company

Irvine, California, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

PHDC’s PULS Cardiac Test™ is commercially available and clinically used for vascular inflammation and cardiac risk stratification; DIABETESpredict™ is marketed for early genetic risk detection in type 2 diabetes; MUSE platform expands PHDC into imaging-based diagnostics

Therapeutic areas: CardiovascularOtherEndocrinology
Modalities: Diagnostic deviceDiagnostic test
Industry: Molecular Diagnostics

Partnerships

Licensed DIABETESpredict testacquired MUSE Microscopy, which involves Lawrence Livermore National Laboratory and UC Davis tech/IP

Beyond the preview

Go deeper on Predictive Health Diagnostics Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Predictive Health Diagnostics Company.

Explore the full profile